BioCentury | Jun 2, 2014
Company News

Valeant Pharmaceuticals, Nestle deal

Valeant will sell its dermal fillers and toxins to Nestle for $1.4 billion in cash. The aesthetics portfolio includes full rights to Sculptra injectable poly-L-lactic acid and U.S. and Canadian rights to commercialize several products...
BioCentury | May 29, 2014
Company News

Valeant ups Allergan bid, divests wrinkle assets for $1.4B

Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) made a new bid for Allergan Inc. (NYSE:AGN) which values Allergan at up to $57.8 billion. The new offer keeps the stock component of 0.83 Valeant shares for each...
BioCentury | Feb 8, 2010
Clinical News

Perlane-L regulatory update

FDA approved Medicis' Perlane-L and Restylane-L to correct moderate to severe facial wrinkles and folds. Perlane-L is indicated for implantation into the deep dermis to superficial subcutis, while Restylane-L is indicated for implantation into the...
BioCentury | Mar 19, 2007
Company News

Adventrx management update

...Yelmene as VP of regulatory affairs, formerly executive director of clinical and regulatory affairs at Perlan Therapeutics Inc. WIR...
BioCentury | Sep 23, 2002
Company News

Kaleidos Pharma Inc. management update

...he replaces Thomas Felker, who remains chairman; and John Reno as president, formerly president of Perlan...
Items per page:
1 - 5 of 5
BioCentury | Jun 2, 2014
Company News

Valeant Pharmaceuticals, Nestle deal

Valeant will sell its dermal fillers and toxins to Nestle for $1.4 billion in cash. The aesthetics portfolio includes full rights to Sculptra injectable poly-L-lactic acid and U.S. and Canadian rights to commercialize several products...
BioCentury | May 29, 2014
Company News

Valeant ups Allergan bid, divests wrinkle assets for $1.4B

Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) made a new bid for Allergan Inc. (NYSE:AGN) which values Allergan at up to $57.8 billion. The new offer keeps the stock component of 0.83 Valeant shares for each...
BioCentury | Feb 8, 2010
Clinical News

Perlane-L regulatory update

FDA approved Medicis' Perlane-L and Restylane-L to correct moderate to severe facial wrinkles and folds. Perlane-L is indicated for implantation into the deep dermis to superficial subcutis, while Restylane-L is indicated for implantation into the...
BioCentury | Mar 19, 2007
Company News

Adventrx management update

...Yelmene as VP of regulatory affairs, formerly executive director of clinical and regulatory affairs at Perlan Therapeutics Inc. WIR...
BioCentury | Sep 23, 2002
Company News

Kaleidos Pharma Inc. management update

...he replaces Thomas Felker, who remains chairman; and John Reno as president, formerly president of Perlan...
Items per page:
1 - 5 of 5